Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients.

Front Pharmacol · 2025 · PMC11825824 · PMID 39959424

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significanceP = 0.130not close (p > 0.1)

58.8%, P = 0.044); however, the DCR difference between these groups did not reach statistical significance (96.1% vs. 94.0%, P = 0.130). 4 Discussion The findings from this study indicated that 43.4% (1096/2523) of the cases encountered irAEs, while 20.4% (517/2523) experienced multiple irAEs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.